Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q4 Earnings? What You Should Know

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.

What's in the Cards for Intellia (NTLA) This Earnings Season?

Vertex Pharmaceuticals

Our indicative theme of Gene Editing Stocks is up by about 187% since the end of 2018 and by about 5% year-to-date. Gene editing has received more attention this year, as scientists used the technology to cure progeria syndrome in mice, raising hopes for therapy in humans as well.

Vertex, Intellia Therapeutics: Gene Editing Stocks To Watch

It's been a long, long journey… but we are finally at the point where genomics is ready to change the world. The post A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains appeared first on InvestorPlace.

A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains

Editas Medicine

Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indicative theme on Gene Editing Stocks has returned over 170% since the end of 2018, compared to the.

Intellia, Editas: How Are Gene Editing Stocks Faring?

Beam Therapeutics

CRISPR Therapeutics

SpringWorks Therapeutics Inc

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

Beam, SpringWorks Biggest Gainers on BioSpace List

Cellectis SA

Calyxt

Sangamo Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medical condition with healthy versions.

CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla

We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifically in genomics.

Is Intellia a Buy after its early success this year?

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The post Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs appeared first on Investor's Business Daily.

Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

3 Biotech Technological Developments to Watch Out For in 2021

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today outlined its expected 2021 milestones and the following strategic priorities:

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

CymaBay Therapeutics

Marinus Pharmaceuticals

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

5 Disruptive Biotech Stocks With Solid Long-Term Potential

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today

Fate Therapeutics

Moderna

Mersana Therapeutics

Ultragenyx Pharmaceutical

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

5 Biotech Stocks That Have Gained More Than 200% in 2020

Intellia is overshadowed a bit by its cousins Editas & CRISPR Therapeutics, however Intellia has a rich pipeline that looks to be focused on a few opportunities outside of its competition. The stock has rocketed up near the end of 2020 by almost 300%, however the party, long term is still accepting RSVP's.

Intellia Therapeutics: The Smallest Of The Big 3 CRISPR Companies Has Big Potential

uniQure

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives

Demonstrates modularity of Intellia's in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy

Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

In the Century of Biology, it pays to own the future of curing disease at the root.

CRISPR Gene Editing: Owning the Future of Medicine

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company's wholly owned Wilms' Tumor 1 (WT1)-directed T cell receptor (TCR)-T cell therapy candidate for the treatment of acute myeloid leukemia (AML), at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020. NTLA-5001 capitalizes on how natural T cells recognize and respond to tumors. The target, WT1, is highly overexpressed in AML, a cancer of the blood and bone marrow that is often fatal despite existing treatments (NIH SEER Cancer Stat Facts: Leukemia – AML). The new preclinical data being presented today highlight the faster expansion and superior function of T cells manufactured by Intellia's proprietary approach, compared to a standard genome editing process. Specifically, NTLA-5001's lead TCR-T cells resulted in significantly higher anti-tumor activity in mouse models of acute leukemias than that observed in mice treated with cells engineered using the standard process.

Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public offering of 5,513,699 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 719,178 shares, at the public offering price of $36.50 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and expenses of the offering, were approximately $201 million.

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

News for Intellia Therapeutics Stock (NTLA)